Menu
Dr Kieren Po’s research aims to understand what treatments are being used by people with multiple sclerosis (MS), how treatments are chosen and monitored, how well people stay on treatments and the reasons why. This will be achieved through the analysis of data obtained from people with MS and clinicians. Â
Ultimately, this research aims to advance understanding of the contemporary MS treatment landscape in different care settings, and may help people with MS and their treating doctors with their treatment decisions.Â
Over the past year, Dr Po has developed his study’s background and methodology. Data on the use of disease modifying therapies (DMTs) in Australia over a five-year period has been obtained and is being analysed. This has shown that overall use of DMTs in Australia has increased over time. The most widely used DMTs in Australia in people with MS are anti-CD20 monoclonal antibodies (ocrelizumab and ofatumumab). There is a trend over time towards increasing use of highly effective therapies and decreasing use of injectable therapies.Â
The design of the DMT selection and adherence parts of the project have been finalised. Participant recruitment is now underway for the DMT selection component while potential participants have been identified for the adherence component.Â
The design of the ocrelizumab real-world component of the project is being finalised and preliminary registry-based data has been collected. This part of the project aims to understand how ocrelizumab is used in the real world in Australia. Preliminary data shows that ocrelizumab is highly effective and is well-tolerated.Â
Updated 31 March 2024Â
$52,500
2023
3 years
Current project
